These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

220 related articles for article (PubMed ID: 12659641)

  • 1. Cost of managing complications resulting from type 2 diabetes mellitus in Canada.
    O'Brien JA; Patrick AR; Caro JJ
    BMC Health Serv Res; 2003 Mar; 3(1):7. PubMed ID: 12659641
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Diabetes in Canada: direct medical costs of major macrovascular complications.
    O'Brien JA; Caro I; Getsios D; Caro JJ
    Value Health; 2001; 4(3):258-65. PubMed ID: 11705187
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Estimates of direct medical costs for microvascular and macrovascular complications resulting from type 2 diabetes mellitus in the United States in 2000.
    O'Brien JA; Patrick AR; Caro J
    Clin Ther; 2003 Mar; 25(3):1017-38. PubMed ID: 12852716
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Direct medical costs of complications resulting from type 2 diabetes in the U.S.
    O'Brien JA; Shomphe LA; Kavanagh PL; Raggio G; Caro JJ
    Diabetes Care; 1998 Jul; 21(7):1122-8. PubMed ID: 9653606
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Assessing the impact of complications on the costs of Type II diabetes.
    Williams R; Van Gaal L; Lucioni C;
    Diabetologia; 2002 Jul; 45(7):S13-7. PubMed ID: 12136406
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Health Care Costs Associated With Incident Complications in Patients With Type 2 Diabetes in Germany.
    Kähm K; Laxy M; Schneider U; Rogowski WH; Lhachimi SK; Holle R
    Diabetes Care; 2018 May; 41(5):971-978. PubMed ID: 29348194
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Health Care Costs Associated With Macrovascular, Microvascular, and Metabolic Complications of Type 2 Diabetes Across Time: Estimates From a Population-Based Cohort of More Than 0.8 Million Individuals With Up to 15 Years of Follow-up.
    Chen HY; Kuo S; Su PF; Wu JS; Ou HT
    Diabetes Care; 2020 Aug; 43(8):1732-1740. PubMed ID: 32444454
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Annual direct medical costs associated with diabetes-related complications in the event year and in subsequent years in Hong Kong.
    Jiao F; Wong CKH; Tang SCW; Fung CSC; Tan KCB; McGhee S; Gangwani R; Lam CLK
    Diabet Med; 2017 Sep; 34(9):1276-1283. PubMed ID: 28636749
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Review of the cost of diabetes complications in Australia, Canada, France, Germany, Italy and Spain.
    Ray JA; Valentine WJ; Secnik K; Oglesby AK; Cordony A; Gordois A; Davey P; Palmer AJ
    Curr Med Res Opin; 2005 Oct; 21(10):1617-29. PubMed ID: 16238902
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Cost-effectiveness of the diabetes care protocol, a multifaceted computerized decision support diabetes management intervention that reduces cardiovascular risk.
    Cleveringa FG; Welsing PM; van den Donk M; Gorter KJ; Niessen LW; Rutten GE; Redekop WK
    Diabetes Care; 2010 Feb; 33(2):258-63. PubMed ID: 19933991
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Direct medical costs of complications of diabetes in the United States: estimates for event-year and annual state costs (USD 2012).
    Ward A; Alvarez P; Vo L; Martin S
    J Med Econ; 2014 Mar; 17(3):176-83. PubMed ID: 24410011
    [TBL] [Abstract][Full Text] [Related]  

  • 12. The direct medical cost of type 2 diabetes.
    Brandle M; Zhou H; Smith BR; Marriott D; Burke R; Tabaei BP; Brown MB; Herman WH
    Diabetes Care; 2003 Aug; 26(8):2300-4. PubMed ID: 12882852
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Total and component health care costs in a non-Medicare HMO population of patients with and without type 2 diabetes and with and without macrovascular disease.
    Gandra SR; Lawrence LW; Parasuraman BM; Darin RM; Sherman JJ; Wall JL
    J Manag Care Pharm; 2006 Sep; 12(7):546-54. PubMed ID: 16981800
    [TBL] [Abstract][Full Text] [Related]  

  • 14. The costs of treating long-term diabetic complications in a developing country: a study from India.
    Kumpatla S; Kothandan H; Tharkar S; Viswanathan V
    J Assoc Physicians India; 2013 Feb; 61(2):102-9. PubMed ID: 24471248
    [TBL] [Abstract][Full Text] [Related]  

  • 15. The impact of diabetes-related complications on healthcare costs: results from the United Kingdom Prospective Diabetes Study (UKPDS Study No. 65).
    Clarke P; Gray A; Legood R; Briggs A; Holman R
    Diabet Med; 2003 Jun; 20(6):442-50. PubMed ID: 12786677
    [TBL] [Abstract][Full Text] [Related]  

  • 16. The progressive cost of complications in type 2 diabetes mellitus.
    Brown JB; Pedula KL; Bakst AW
    Arch Intern Med; 1999 Sep; 159(16):1873-80. PubMed ID: 10493317
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Economic outcomes associated with microvascular complications of type 2 diabetes mellitus: results from a US claims data analysis.
    Pelletier EM; Shim B; Ben-Joseph R; Caro JJ
    Pharmacoeconomics; 2009; 27(6):479-90. PubMed ID: 19640011
    [TBL] [Abstract][Full Text] [Related]  

  • 18. The health care costs of diabetic peripheral neuropathy in the US.
    Gordois A; Scuffham P; Shearer A; Oglesby A; Tobian JA
    Diabetes Care; 2003 Jun; 26(6):1790-5. PubMed ID: 12766111
    [TBL] [Abstract][Full Text] [Related]  

  • 19. A model to estimate cost-savings in diabetic foot ulcer prevention efforts.
    Barshes NR; Saedi S; Wrobel J; Kougias P; Kundakcioglu OE; Armstrong DG
    J Diabetes Complications; 2017 Apr; 31(4):700-707. PubMed ID: 28153676
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Using Phase-Based Costing of Real-World Data to Inform Decision-Analytic Models for Atrial Fibrillation.
    Tawfik A; Wodchis WP; Pechlivanoglou P; Hoch J; Husereau D; Krahn M
    Appl Health Econ Health Policy; 2016 Jun; 14(3):313-22. PubMed ID: 26924098
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 11.